Virtu Financial’s Lexaria Bioscience LEXX Stock Holding History

Virtu Financial’s Portfolio LEXX Stock Details LEXX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1,957	Closed	-$28K	–	1971
2025 Q3	$28K	Buy	+1,957	New	+$28.4K	﹤0.01%	1235
2022 Q3	–	Sell	-732	Closed	-$33K	–	1990
2022 Q2	$33K	Sell	732 -70	-9%	-$2.81K	﹤0.01%	1230
2022 Q1	$40K	Buy	+802	New	+$45.4K	﹤0.01%	1184
2021 Q4	–	Sell	-796	Closed	-$75K	–	1965
2021 Q3	$75K	Buy	+796	New	+$76.3K	0.01%	1208

Other funds holding LEXX

ICM

Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

BAM

Byrne Asset Management Kingston, New Jersey $185M AUM 41.05% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Krilogy Financial St. Louis, Missouri $3.38B AUM 30.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Virtu Financial's LEXX Position: Q4 2025 in Review

Virtu Financial sold out of Lexaria Bioscience (LEXX) in Q4 2025, closing a stake of 1,957 shares — an estimated $28K sold.

Virtu Financial first reported a position in LEXX in Q3 2021 and held it in 4 quarters. The position peaked at $75K in Q3 2021. 20 funds tracked by Wall St. Rank hold LEXX as of Q4 2025.

Virtu Financial reported no remaining Lexaria Bioscience position as of Q4 2025 after selling out during the quarter.
Virtu Financial sold 1,957 Lexaria Bioscience shares in Q4 2025, an estimated $28K.
Virtu Financial first reported a position in Lexaria Bioscience in Q3 2021 and held it in 4 quarters.
Virtu Financial's Lexaria Bioscience position peaked at $75K in Q3 2021.
20 funds tracked by Wall St. Rank held Lexaria Bioscience as of Q4 2025.

Based on Virtu Financial's 13F filing for Q4 2025, filed 23 Feb 2026.